ReActiv8 Implantable Neurostimulation System
Mainstay Medical Limited · Decision date Oct 19, 2026
What did the FDA approve?
The FDA record for P190021/S012 describes a real-time process supplement to the ReActiv8 implantable neurostimulation system PMA held by Mainstay Medical Limited. The stated purpose is approval of revised magnetic resonance compatibility labeling in the ReActiv8 System Magnetic Resonance Imaging (MRI) Guidelines manual, now covering lead fragments up to 2 cm in length. The supplement carries a labeling-change reason tied to indications, instructions, shelf life, or tradename, and sits in the neuromuscular lower-back stimulator category for pain relief.
The identifier shows P190021 is the original PMA, so S012 is a supplement, not a new approval of the whole system. The record does not explain the prior lead-fragment limit, how the 2 cm figure was derived, or what testing supports it; the approval reflects the agency's labeling decision, not an independent finding of safety or clinical effectiveness reported here. Details on MRI field conditions and the full manual text remain absent from the supplied fields.
FDA approval order statement
approval for revised magnetic resonance (MR) compatibility labeling in the ReActiv8 System Magnetic Resonance Imaging (MRI) Guidelines manual to include lead fragments up to 2 cm in length.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Neurology
- Decision date
- Oct 19, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P190021/S012
- Regulatory pathway
- PMA supplement
- Applicant
- Mainstay Medical Limited
- Product code
- QLK
- Decision code
- APPR
- Decision date
- Oct 19, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, neuromuscular, lower back muscles, totally implanted for pain relief.
- Applicant
- Mainstay Medical Limited
- Product code
- QLK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P190021. Subsequent supplements may change the device or its indications.
FDA decision timeline
P190021 · Original PMA
ReActiv8 Implantable Neurostimulation System
P190021/S012 received
Application receipt date recorded by FDA.
P190021/S012 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P190021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Mainstay Medical Limited | PMA approval | Jun 16, 2020 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Mainstay Medical Limited
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Clonmel House Forster Way, Swords, Co Dublin, K67F2K3
Sources and methodology
- Original FDA record: P190021/S012
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records